An open-label efficacy pilot study with pimecrolimus cream 1% in adults with facial seborrhoeic dermatitis infected with HIV

Journal of the European Academy of Dermatology and Venereology

Volumn 21, Issue 5, 2007, Pages 596-601

  de Moraes, Andy P ^a,c   De Arruda, E A G ^a   Vitoriano, M A V ^a   de Moraes Filho, M O ^a   Bezerra, F A F ^a   de Magalhaes Holanda E ^b  

^a FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^b Hospital Monte Klinikum Fortaleza Ceará   (Brazil)

^c NONE   (Brazil)

Author keywords

HIV positive; Pimecrolimus; Seborrhoeic dermatitis; Treatment

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; PIMECROLIMUS;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREAM; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MEDICAL PHOTOGRAPHY; OPEN STUDY; PATIENT COMPLIANCE; PILOT STUDY; PRIORITY JOURNAL; RELAPSE; SCORING SYSTEM; SEBORRHEIC DERMATITIS; UNSPECIFIED SIDE EFFECT; VIRUS LOAD;

EID: 34250332955     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2006.01923.x     Document Type: Article

References (16)

1. Gupta AK, Madzia SE, Batra R. Etiology and management of seborrheic dermatitis. Dermatology 2004; 208: 89-93.
2. Gupta AK, Bluhm R. Seborrheic dermatitis. J Eur Acad Dermatol Venereol 2004; 18: 13-26.
3. Jansen T, Plewig G. Seborrheic dermatitis. In: Freedberg IM, Eisen AZ, Wolff K et al. Fitzpatrick's Dermatology in General Medicine, Vol. I, 5th edn. McGraw-Hill, New York, 1999, 1482-1489.
4. Schaub NA, Drewe J, Sponagel L et al. Is there a relation between risk groups or initial CD4 T cell counts and prevalence of seborrheic dermatitis in HIV-infected patients? Dermatology 1999; 198: 126-129.
5. Reynaud-Mendel B, Janier M, Gerbaka J et al. Dermatologic findings in HIV-1-infected patients: A prospective study with emphasis on CD4+ cell count. Dermatology 1996; 192: 325-328.
6. Thiers BH. Treatment of skin diseases in HIV infected patients. Dermatol Clin 1995; 13: 231-238.
7. Crutchfield CE 3rd. Pimecrolimus: A new treatment for seborrheic dermatitis. Cutis 2002; 70: 207-208.
8. Ling MR. Topical tacrolimus and pimecrolimus: Future directions. Semin Cutan Med Surg 2001; 20: 268-274.
9. Wolff K, Stuetz A. Pimecrolimus for the treatment of inflammatory skin disease. Exp Opin Pharmacother 2004; 5: 643-655.
10. Hultsch T, Spergel J. Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Dermatology 2005; 211: 174-187.
11. Kempers S, Boguniewicz M, Carter E et al. A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. J Am Acad Dermatol 2004; 51: 515-525.
12. Brownell I, Quan LT, Hsu S. Topical pimecrolimus in the treatment of seborrheic dermatitis. Dermatol Online J 2003; 9: 13.
13. Rigopoulos D, Ioannides D, Kalogeromitros D et al. Pimecrolimus cream 1% vs. betamethasone 17-valerate cream 0.1% in the treatment of seborrhoeic dermatitis. A randomized open-label clinical trial. Br J Dermatol 2004; 151: 1071-1075.
14. Moraes AP, Arruda EAG, Moraes MEA. Facial seborrheic dermatitis treated with pimecrolimus cream in four patients HIV positive. J Brasileiro Aids 2004; 5: 111-114.
15. Ippolito F, Passi S, Di Carlo A. Is seborrhoeic dermatitis a clinical marker of HIV disease? Minerva Ginecol 2000; 52 (Suppl. 1): 54-58.
16. Sadick NS, McNutt NS, Kaplan MH. Papulosquamous dermatoses of AIDS. J Am Acad Dermatol 1990; 22: 1270-1277.